Advertisement
Genaera research scientists concluded that treatment with MSI-1436 leadsto marked improvement in glucose tolerance and lowers plasma insulin levels indiet-induced obese (DIO) mice and improves fasting blood glucose and glucosetolerance in hyperglycemic animal models, and that these effects aremaintained over time. In one study, the researchers reported that four weeklytreatments of MSI-1436 administered to DIO mice resulted in significantreductions in plasma insulin levels. Additionally, hyperglycemic (Ob/Ob) micetreated with weekly doses of MSI-1436 for 122 days demonstrated that thesignificant improvements in glucose tolerance, as measured by oral glucosetolerance testing can be sustained during long periods of therapy. Thescientists concluded that the anti-diabetic properties of MSI-1436 includedimproved insulin sensitivity, lowering of plasma insulin levels and durableimprovements in fasting blood glucose and glucose tolerance.
Advertisement
"This encouraging preclinical work continues to provide strong basicscience support and direction for our efforts to explore MSI-1436 as a therapyfor type 2 diabetes," stated Jack Armstrong, President and Chief ExecutiveOfficer of Genaera. "With our recent investigational new drug (IND) filing fortype 2 diabetes now in effect and the positive metabolic data from our firstcompleted Phase 1 study in obesity, we are executing upon our strategy toevaluate the potential of MSI-1436 to impact both type 2 diabetes andobesity."
The poster entitled "Trodusquemine (MSI-1436) Enhances Glucose Tolerancein a Murine Model of Insulin Resistance" will be displayed from 7:30 p.m. to10:00 p.m. MT at the Beaver Run Resort in Breckenridge, Colorado.
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressantand the first highly selective inhibitor of protein tyrosine phosphatase 1B(PTP-1B). PTP-1B is central to controlling the function of both the leptin andinsulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decreaseappetite and normalize blood sugar. Trodusquemine has produced consistent,sustainable weight loss in a variety of animal models and appears to overcomemetabolic readjustment, which often limits sustained weight loss duringcaloric restriction. In addition, trodusquemine has shown the ability toreverse co-morbidities associated with obesity such as abnormal glucosemetabolism and cholesterol elevation.
About Genaera
Genaera Corporation is focused on advancing the science and treatment ofmetabolic diseases. The Company has significant market opportunities with afirst-in-class molecule, trodusquemine (MSI-1436), that has the potential toredefine the treatment paradigm for obesity and type 2 diabetes and ispresently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second coreprogram that is presently undergoing Phase 2 clinical testing in asthma.Genaera is committed to directing resources to its core program and theaggressive clinical development of its key assets to build stockholder value.For further information, please see our website at http://www.genaera.com.
This announcement contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that are subject torisks and uncertainties, known and unknown. Forward-looking statements reflectmanagement's current views and are based on certain expectations andassumptions. Such statements include, among others, statements regarding
